Citadel Advisors
ORGO icon

Citadel Advisors’s Organogenesis Holdings ORGO Stock Holding History

Citadel Advisors’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Buy
867,929
+323,694
+59% +$791K ﹤0.01% 6432
2026
Q1 		$1.29M Sell
544,235
-24,931
-4% -$86.4K ﹤0.01% 7090
2025
Q4 		$2.95M Buy
+569,166
New +$2.76M ﹤0.01% 5196
2025
Q3 		– Sell
-100,779
Closed -$468K – 13731
2025
Q2 		$369K Sell
100,779
-135,951
-57% -$507K ﹤0.01% 9336
2025
Q1 		$1.02M Sell
236,730
-19,071
-7% -$77K ﹤0.01% 6907
2024
Q4 		$819K Buy
255,801
+117,947
+86% +$396K ﹤0.01% 7462
2024
Q3 		$394K Sell
137,854
-46,363
-25% -$130K ﹤0.01% 8752
2024
Q2 		$516K Sell
184,217
-43,714
-19% -$117K ﹤0.01% 7976
2024
Q1 		$647K Sell
227,931
-230,861
-50% -$785K ﹤0.01% 7815
2023
Q4 		$1.88M Sell
458,792
-159,982
-26% -$448K ﹤0.01% 5474
2023
Q3 		$1.97M Sell
618,774
-1,242,416
-67% -$3.95M ﹤0.01% 5244
2023
Q2 		$6.18M Sell
1,861,190
-690,700
-27% -$2.04M ﹤0.01% 3319
2023
Q1 		$5.44M Buy
2,551,890
+1,876,307
+278% +$4.64M ﹤0.01% 3671
2022
Q4 		$1.82M Sell
675,583
-451,546
-40% -$1.32M ﹤0.01% 5653
2022
Q3 		$3.65M Buy
1,127,129
+383,714
+52% +$1.73M ﹤0.01% 4422
2022
Q2 		$3.63M Sell
743,415
-43,881
-6% -$270K ﹤0.01% 4409
2022
Q1 		$6M Buy
787,296
+580,717
+281% +$4.49M ﹤0.01% 3827
2021
Q4 		$1.91M Sell
206,579
-225,522
-52% -$2.4M ﹤0.01% 6355
2021
Q3 		$6.15M Sell
432,101
-158,456
-27% -$2.46M ﹤0.01% 3926
2021
Q2 		$9.81M Buy
590,557
+78,946
+15% +$1.47M ﹤0.01% 3110
2021
Q1 		$9.32M Buy
511,611
+385,068
+304% +$5.22M ﹤0.01% 3075
2020
Q4 		$953K Buy
+126,543
New +$601K ﹤0.01% 6899
2020
Q2 		– Sell
-23,715
Closed -$77K – 10301
2020
Q1 		$77K Sell
23,715
-39,213
-62% -$168K ﹤0.01% 8808
2019
Q4 		$303K Buy
62,928
+43,247
+220% +$274K ﹤0.01% 7570
2019
Q3 		$129K Sell
19,681
-6,631
-25% -$36.9K ﹤0.01% 8365
2019
Q2 		$200K Buy
+26,312
New +$193K ﹤0.01% 8189

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citadel Advisors's ORGO Position: Q2 2026 in Review

Citadel Advisors increased its Organogenesis Holdings (ORGO) stake by 59% in Q2 2026, buying an estimated $791K and bringing the position to 867,929 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #6432.

Citadel Advisors first reported a position in ORGO in Q2 2019 and has held it in 26 quarters since. The position peaked at $9.81M in Q2 2021. 135 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • Citadel Advisors held 867,929 shares of Organogenesis Holdings worth $2.11M as of Q2 2026.
  • Citadel Advisors bought 323,694 Organogenesis Holdings shares in Q2 2026, an estimated $791K.
  • Organogenesis Holdings made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6432 holding.
  • Citadel Advisors first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 26 quarters since.
  • Citadel Advisors's Organogenesis Holdings position peaked at $9.81M in Q2 2021.
  • 135 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.